Northwell Health Named one of the Healthiest Workplaces in America

December 28, 2020

Northwell Health has been recognized as one of the Healthiest 100 Workplaces in America, a distinction given to organizations that prioritize the well-being of their employee populations.

Northwell Health placed 81st in the country and is being honored for a commitment to workplace wellness and exceptional health and benefits for healthcare professionals. Springbuk, a health intelligence software platform, names 100 organizations for this designation every year.

Northwell offers employees a wide range of resources to improve their health and physical well-being from yearly team step challenges, wellness workshops, weight management, breastfeeding support, emotional and spiritual well-being resources and the system’s Healthy Choice food recommendations.

Some of the benefits Northwell offers employees include: the coronavirus disease 2019 (COVID-19) team member vaccination program, diagnostic COVID-19 testing for employees and their family members, overnight virtual emergency care, child care benefits, fertility and surrogacy benefits, behavioral health navigation, seasonal affective disorder counseling as well as a confidential emotional support call center that operates 24 hours a day, seven days a week.

“Our employees are on a mission to improve the lives of others, and the way to do that is to help them improve their own lives,” said Patricia Flynn, associate vice president for employee wellness at Northwell. “The Northwell Health commitment to employee well-being runs deep. This year we’ve doubled down on updating benefits and delivering wellness programs that take into account the current pandemic environment. The goal is to help our employees and their families become healthier by providing them with multiple wellness touch points that keep them engaged and can be incorporated into their daily routine.”

When compiling their list of healthiest employers, Springbuk evaluated workplaces across six key categories: Culture and leadership, foundational components, strategic planning, communication and marketing, programming and interventions and reporting and analytics.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”